Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023)
Exelixis (EXEL) posted quarterly Non-Current Deffered Revenue of $6.7 million for Q2 2023, down 6.73% year-over-year from $7.2 million in Q2 2022, and up 6.75% quarter-over-quarter from $6.3 million in Q1 2023.
Analysis
Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends
Exelixis' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $6.7 million for Q2 2023.
- In Q2 2023, Non-Current Deffered Revenue fell 6.73% year-over-year to $6.7 million; the TTM figure through Jun 2023 stood at $6.7 million (down 6.73% YoY), while the FY2022 annual figure was $6.6 million, down 24.68% from the prior year.
- Non-Current Deffered Revenue for Q2 2023 stood at $6.7 million, up from $6.3 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $16.6 million in Q2 2019, with the low at $3.8 million in Q1 2021.
- The 5-year median for Non-Current Deffered Revenue is $8.4 million (2019), against an average of $9.3 million.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue soared 579.01% in 2019, then plunged 58.51% in 2020.
- Exelixis' Non-Current Deffered Revenue stood at $15.4 million in 2019, then sank by 39.47% to $9.3 million in 2020, then decreased by 6.25% to $8.7 million in 2021, then declined by 24.68% to $6.6 million in 2022, then increased by 2.16% to $6.7 million in 2023.
- Business Quant data shows EXEL's Non-Current Deffered Revenue at $6.7 million in Q2 2023, $6.3 million in Q1 2023, and $6.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 6.72 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 30, 2022 | 6.58 Mn |
| Sep 30, 2022 | 6.49 Mn |
| Jul 1, 2022 | 7.21 Mn |
| Apr 1, 2022 | 8.04 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Oct 1, 2021 | 9.44 Mn |
| Jul 2, 2021 | 8.58 Mn |
| Apr 2, 2021 | 9.76 Mn |
| Jan 1, 2021 | 3.76 Mn |
| Oct 2, 2020 | 9.32 Mn |
| Jul 3, 2020 | 15.00 Mn |
| Apr 3, 2020 | 14.13 Mn |
| Jan 3, 2020 | 6.60 Mn |
| Sep 27, 2019 | 15.40 Mn |
| Jun 28, 2019 | 16.63 Mn |
| Mar 29, 2019 | 8.32 Mn |
| Dec 28, 2018 | 15.90 Mn |
| Sep 28, 2018 | 2.27 Mn |